Blockade of dopamine D3 receptors in the nucleus accumbens and central amygdala inhibits incubation of cocaine craving in rats.
Cue-induced drug seeking progressively increases over time of withdrawal from drug self-administration in rats, a phenomenon called 'incubation of craving'. The underlying mechanisms have been linked to increased expression of brain-derived neurotrophic factor and GluR2-lacking AMPA receptors in the mesolimbic dopamine (DA) system and also to increased extracellular signal-regulated kinase activation in the central amygdala (CeA). However, it remains unclear whether any DA mechanism is also involved in incubation of craving. Recent research demonstrates that cue-induced cocaine seeking appears to parallel increased DA D3 , but not D1 or D2 , receptor expression in the nucleus accumbens (NAc) of rats over time of withdrawal, suggesting possible involvement of D3 receptors (D3 Rs) in incubation of cocaine craving. Here, we report that systemic or local administration of SB-277011A, a highly selective D3 R antagonist, into the NAc (core and shell) or the CeA, but not the dorsal striatum or basolateral amygdala, significantly inhibits expression of incubation of cocaine craving in rats after 2-30 days of withdrawal from previous cocaine self-administration but had no effect on sucrose-seeking behavior in rats after 10-30 days of withdrawal. These data suggest that DA D3 Rs in both the NAc and the CeA play an important role in incubation of cocaine craving in rats and support the potential utility of D3 R antagonists in the treatment of cocaine addiction.
Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA.
Zheng-Xiong
ZX
Xi
Xia
X
Li
Jie
J
Li
Xiao-Qing
XQ
Peng
Rui
R
Song
József
J
Gaál
Eliot L
EL
Gardner
D000679:Amygdala / Q000187:drug effects / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D003463:Cues; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D058999:Drug-Seeking Behavior / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008845:Microinjections; D009570:Nitriles / Q000008:administration & dosage / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D012054:Reinforcement, Psychology; D055502:Secondary Prevention; D012646:Self Administration / Q000379:methods; D013395:Sucrose / Q000008:administration & dosage; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D018492:Dopamine Antagonists; D009570:Nitriles; D050637:Receptors, Dopamine D3; C409982:SB 277011; D044005:Tetrahydroisoquinolines; D013395:Sucrose; D003042:Cocaine